Healthcare
Live Price
Offline$4.23
+13.40% today
1Y Change
-31.71%
Window
Jun 23, 2025 → Jun 15, 2026
Coverage: 246 bars · Jun 23, 2025 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Treace Medical Concepts, Inc. (TMCI) is a Healthcare stock with a market cap of $120.00M and listed on NASDAQ. The stock last traded around $4.23 and down 31.7% across the available one-year price window (Jun 23, 2025 → Jun 15, 2026). Baseline metrics include revenue growth of +1.6%, EPS growth of -3.3%, a dividend yield of 0.0%. What stands out right now is revenue +1.6%, EPS -3.3%, free cash flow +39.5% with operating margin -25.5% and ROIC -33.9%. Valuation is more restrained than many high-expectation growth names at price/sales 0.6. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines TMCI price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TMCI
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
TMCI Max Drawdown
-84.42%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for TMCI and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$94.4M
-33.4% YoY
FY Net Income
-$20.6M
+52.0% YoY
Free Cash Flow
-$19.9M
+56.3% YoY
Revenue Growth
+1.6%
EPS Growth
-3.3%
Gross Margin
79.8%
Net Margin
-27.7%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 213M | 209M | 187M | 142M | 94M |
| Gross Profit | 170M | 168M | 152M | 114M | 78M |
| Operating Income | -54M | -56M | -51M | -35M | -17M |
| EBITDA | -43M | -42M | -39M | -36M | -16M |
| Net Income | -59M | -56M | -50M | -43M | -21M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 11M | 11M | 13M | 19M | 106M |
| Total Assets | 191M | 217M | 252M | 159M | 141M |
| Total Liabilities | 103M | 104M | 114M | 98M | 48M |
| Shareholder Equity | 87M | 113M | 138M | 61M | 93M |
| Total Debt | 14M | 70M | 70M | 69M | 29M |
| Net Debt | 3M | 58M | 57M | 49M | -76M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
17M
+43.9% YoY
Capital Expenditures
3M
+81.8% YoY
Free Cash Flow
20M
+56.3% YoY
Key ratios
Gross Margin
79.8%
Operating Margin
-25.5%
Net Margin
-27.7%
ROE
-62.2%
Debt / Equity
0.16x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.